Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02948829

Enrollment

200

Registered

2016-10-28

Start date

2017-04-03

Completion date

2020-12-14

Last updated

2024-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

Drug therapy

Brief summary

The purpose of this study is to assess the cellular immune responses following 2 doses given 3 months apart of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy participants.

Detailed description

The vaccine tested in this study was TDV. This study assessed cellular immune responses and safety up to 3 years post second TDV administration to healthy children aged 4 to 16 years and in dengue endemic regions. The study enrolled 200 participants. Participants received: • TDV 0.5 mL subcutaneous (SC) injection into the upper arm at Day 1 (Month 0) and at Day 90 (Month 3). This multi-center trial was conducted in Panama and Philippines. 198 participants received the 2-dose schedule of TDV, and 2 participants received only the first dose of TDV (Day 1). Participants made multiple visits to the clinic and were contacted at least every week for the entire study duration post first injection.

Interventions

BIOLOGICALTDV

TDV SC injection.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

4 Years to 16 Years

Healthy volunteers

Yes

Inclusion criteria

Main Inclusion Criteria: 1. Is aged 4 to 16 years, inclusive (Latin America) or 4 to 8 years, inclusive (Asia). 2. Are in good health at the time of entry into the study as determined by medical history, physical examination (including vital signs), and clinical judgment of the investigator. Main

Exclusion criteria

1. Febrile illness (body temperature ≥38°C) or moderate or severe acute illness or infection at the time of enrolment. 2. History or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose an additional risk to the participant due to participation in the study. 3. Receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Day 1 (Month 0) or planning to receive any vaccines within 28 days after Day 1 (Month 0). 4. Previous participation in any clinical study of a dengue candidate vaccine, or previous receipt of any dengue vaccines (investigational or licensed).

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination	1 month post second vaccination (Day 120)	Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural proteins (NS) NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentage of participants with cellular immune response were reported. Percentages are rounded off to the nearest decimal point.

Secondary

Measure	Time frame	Description
Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Day 270); Years 1, 2 and 3	Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentages are rounded off to the nearest decimal point.
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Days 120 and 270); Years 1, 2 and 3	The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2.
Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	1 month post first vaccination (Day 30); pre-second vaccination (Day 90) 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, 3	Percentage of participants with cellular immune response by country were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines). Percentages are rounded off to the nearest decimal point.
Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3	Percentage of participants with cellular immune response by dengue Baseline seropositivity status were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer \>=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer \<10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative). Percentages are rounded off to the nearest decimal point.
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3	The magnitude of cellular immune response by country was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines).
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3	The magnitude of cellular immune response by dengue Baseline seropositivity status was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer \>=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer \<10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative).
Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age	Day 14	Percentage of participants with cellular immune response in participants \>10 years of age were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2.
Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age	Day 14	The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. SFC/million PBMC for any peptide pool is reported in participants \>10 years of age.
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3	The phenotype characterization of cellular immune response was assessed by intracellular cytokine staining (ICS) by the frequency of total cluster of differentiation 4 (CD4)+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses \>500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) cytokines for each peptide pool. Data is reported based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination	1 month post second vaccination (Day 120)	The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2.
Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3	The phenotype characterization of cellular immune response by dengue Baseline seropositivity status was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses \>500 SFC/million cells and availability of sufficient cells. Seropositive was defined as a reciprocal neutralizing titer (MNT50) \>=10 for one or more dengue serotypes. Seronegative was defined as titer value of \<10 for all 4 serotypes. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per Baseline seropositivity status (Seropositive and Seronegative) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)	GMT of neutralizing antibodies was measured by microneutralization test (MTN). The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)	Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)	Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent.
Percentage of Participants Experiencing Unsolicited Adverse Events (AE)	Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]	An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.
Percentage of Participants With Medically Attended AEs (MAAEs)	From first vaccination (Day 1) up to 6 months post second vaccination (Day 270)	MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.
Percentage of Participants With Serious Adverse Events (SAEs)	From first vaccination (Day 1) up to end of study (Approximately 3 years)	A SAE was defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
Percentage of Participants With Virologically Confirmed Dengue	From first vaccination (Day 1) up to 6 months post second vaccination (Day 270)	Participants with febrile illness defined as fever ≥38°C on any 2 of 3 consecutive days were evaluated for dengue. Virologically confirmed dengue was defined as febrile illness with a positive serotype-specific RT-PCR (i.e. positive dengue detection RT-PCR).
Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3	The phenotype characterization of cellular immune response by country was assessed by ICS by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses \>500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per country (Panama and Philippines) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).

Countries

Panama, Philippines

Participant flow

Recruitment details

Participants took part in the study at 2 investigative sites in Panama and Philippines from 03 April 2017 to 14 December 2020.

Pre-assignment details

Healthy participants were enrolled in a single arm in this study to receive 2 doses of Tetravalent Dengue Vaccine (TDV) injection subcutaneously (SC).

Participants by arm

Arm	Count
Tetravalent Dengue Vaccine (TDV) 0.5 mL TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).	200
Total	200

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Lost to Follow-up	2
Overall Study	Other: Reason not Specified	8
Overall Study	Pregnancy	1
Overall Study	Withdrawal by Subject and/or Subject's Parent(s)/ Legally Authorized Representative (LAR)	5

Baseline characteristics

Characteristic	Tetravalent Dengue Vaccine (TDV) 0.5 mL
Age, Continuous	6.7 years STANDARD_DEVIATION 2.28
Baseline Seropositivity Status Seronegative	87 Participants
Baseline Seropositivity Status Seropositive	113 Participants
Body Mass Index (BMI)	16.15 kg/m^2 STANDARD_DEVIATION 3.104
Ethnicity (NIH/OMB) Hispanic or Latino	99 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	101 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Height	118.38 cm STANDARD_DEVIATION 14.564
Race (NIH/OMB) American Indian or Alaska Native	76 Participants
Race (NIH/OMB) Asian	100 Participants
Race (NIH/OMB) Black or African American	8 Participants
Race (NIH/OMB) More than one race	7 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	9 Participants
Region of Enrollment Panama	100 Participants
Region of Enrollment Philippines	100 Participants
Sex: Female, Male Female	101 Participants
Sex: Female, Male Male	99 Participants
Weight	23.54 kg STANDARD_DEVIATION 10.258

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 200
other Total, other adverse events	66 / 200
serious Total, serious adverse events	11 / 200

Outcome results

Primary

Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination

Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural proteins (NS) NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentage of participants with cellular immune response were reported. Percentages are rounded off to the nearest decimal point.

Time frame: 1 month post second vaccination (Day 120)

Population: Per-Protocol Set (PPS) included all participants from the Full Analysis Set (FAS) who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis.

Arm	Measure	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination	97.1 percentage of participants

Secondary

Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years

GMT of neutralizing antibodies was measured by microneutralization test (MTN). The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame: 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)

Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-1, Day 30	402.3 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-2, Day 30	5482.2 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-3, Day 30	436.1 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-4, Day 30	253.9 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-1, Day 90	271.7 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-2, Day 90	2736.3 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-3, Day 90	218.7 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-4, Day 90	177.4 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-1, Day 120	550.6 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-2, Day 120	2808.2 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-3, Day 120	404.2 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-4, Day 120	427.1 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-1, Day 270	343.3 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-2, Day 270	1729.9 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-3, Day 270	203.8 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-4, Day 270	186.6 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-1, Year 1	243.8 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-2, Year 1	896.2 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-3, Year 1	148.6 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-4, Year 1	142.4 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-1, Year 2	290.8 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-2, Year 2	724.7 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-3, Year 2	172.7 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-4, Year 2	157.7 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-1, Year 3	178.7 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-2, Year 3	546.4 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-3, Year 3	125.2 titer
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years	DENV-4, Year 3	91.6 titer

Secondary

Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status

The magnitude of cellular immune response by dengue Baseline seropositivity status was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer \>=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer \<10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative).

Time frame: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3

Population: PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.

Arm	Measure	Group	Value (MEDIAN)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Day 120	1086.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Year 1	275.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Day 90	743.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Year 2	135.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Day 270	592.5 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Year 3	180.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Day 30	1415.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Year 3	103.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Day 30	840.5 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Day 90	473.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Day 120	700.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Day 270	400.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Year 1	132.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status	Year 2	74.0 SFC/million PBMCs

Secondary

Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country

The magnitude of cellular immune response by country was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines).

Time frame: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3

Population: PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint.

Arm	Measure	Group	Value (MEDIAN)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Day 120	780.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Year 1	209.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Day 90	531.5 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Year 2	76.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Day 270	426.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Year 3	147.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Day 30	1019.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Year 3	117.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Day 30	1065.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Day 90	577.5 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Day 120	1003.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Day 270	512.5 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Year 1	178.5 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country	Year 2	124.0 SFC/million PBMCs

Secondary

Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3

The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2.

Time frame: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Days 120 and 270); Years 1, 2 and 3

Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.

Arm	Measure	Group	Value (MEDIAN)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Day 30	1019.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Day 90	536.5 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Day 270	486.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Year 1	193.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Year 2	104.0 SFC/million PBMCs
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Year 3	136.0 SFC/million PBMCs

Secondary

Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age

The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. SFC/million PBMC for any peptide pool is reported in participants \>10 years of age.

Time frame: Day 14

Population: PPS with participants \>10 years of age included all participants from the FAS who have no major protocol violations and are \>10 years of age. The overall number of participants analyzed are the number of participants with data available for analysis at the given timepoint.

Arm	Measure	Value (MEDIAN)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age	227.0 SFC/million PBMCs

Secondary

Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination

Time frame: 1 month post second vaccination (Day 120)

Population: PPS included all participants from the FAS who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis.

Arm	Measure	Value (MEDIAN)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination	846.5 SFC/million PBMCs

Secondary

Percentage of Participants Experiencing Unsolicited Adverse Events (AE)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.

Time frame: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]

Population: Safety Set included all enrolled participants who received at least 1 dose of TDV. Number analyzed is the number of participants with data available for analysis at the given timepoint.

Arm	Measure	Group	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Experiencing Unsolicited Adverse Events (AE)	After First Vaccination	26.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Experiencing Unsolicited Adverse Events (AE)	After Second Vaccination	25.3 percentage of participants

Secondary

Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years

Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame: 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)

Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint.

Arm	Measure	Group	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-1, Day 30	96.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-2, Day 30	99.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-3, Day 30	99.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-4, Day 30	93.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-1, Day 90	90.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-2, Day 90	99.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-3, Day 90	94.4 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-4, Day 90	91.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-1, Day 120	99.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-2, Day 120	100.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-3, Day 120	100.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-4, Day 120	100.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-1, Day 270	96.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-2, Day 270	100.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-3, Day 270	97.9 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-4, Day 270	96.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-1, Year 1	91.1 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-2, Year 1	100.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-3, Year 1	93.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-4, Year 1	96.4 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-1, Year 2	93.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-2, Year 2	100.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-3, Year 2	89.6 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-4, Year 2	95.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-1, Year 3	84.4 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-2, Year 3	100.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-3, Year 3	86.7 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years	DENV-4, Year 3	86.1 percentage of participants

Secondary

Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years

Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent.

Time frame: 1 month post first vaccination (Day 30); pre second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); annually up to 3 years (Years 1, 2 and 3)

Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.

Arm	Measure	Group	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	Tetravalent, Day 30	90.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	At Least Trivalent, Day 30	98.4 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	Tetravalent, Day 90	83.6 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	At Least Trivalent, Day 90	95.4 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	Tetravalent, Day 120	99.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	At Least Trivalent, Day 120	100.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	Tetravalent, Day 270	93.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	At Least Trivalent, Day 270	98.4 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	Tetravalent, Year 1	87.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	At Least Trivalent, Year 1	95.3 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	Tetravalent, Year 2	86.4 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	At Least Trivalent, Year 2	93.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	Tetravalent, Year 3	76.7 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years	At Least Trivalent, Year 3	87.2 percentage of participants

Secondary

Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status

Percentage of participants with cellular immune response by dengue Baseline seropositivity status were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer \>=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer \<10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative). Percentages are rounded off to the nearest decimal point.

Time frame: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3

Arm	Measure	Group	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Day 120	96.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Year 1	87.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Day 90	93.3 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Year 2	80.6 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Day 270	93.1 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Year 3	74.2 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Day 30	91.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Year 3	82.4 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Day 30	100.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Day 90	97.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Day 120	98.6 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Day 270	98.6 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Year 1	94.7 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status	Year 2	89.5 percentage of participants

Secondary

Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country

Percentage of participants with cellular immune response by country were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Data is reported as per enrollment by country (Panama and Philippines). Percentages are rounded off to the nearest decimal point.

Time frame: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90) 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, 3

Population: PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.

Arm	Measure	Group	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Day 120	97.3 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Year 1	91.6 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Day 90	96.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Year 2	86.5 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Day 270	94.7 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Year 3	79.7 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Day 30	96.1 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Year 3	76.1 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Day 30	94.7 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Day 90	93.9 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Day 120	96.9 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Day 270	95.9 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Year 1	90.1 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country	Year 2	82.7 percentage of participants

Secondary

Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3

Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2. Percentages are rounded off to the nearest decimal point.

Time frame: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 6 months post second vaccination (Day 270); Years 1, 2 and 3

Population: PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.

Arm	Measure	Group	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Day 30	95.3 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Day 90	95.1 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Day 270	95.4 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Year 1	90.8 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Year 2	84.0 percentage of participants
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3	Year 3	77.8 percentage of participants

Secondary

Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age

Percentage of participants with cellular immune response in participants \>10 years of age were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was \>3 times higher compared to Baseline (Day 1 \[M0\]) and \>=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS3 and NS5 for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4 and NS1 for DENV-2.

Time frame: Day 14

Arm	Measure	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age	70.0 percentage of participants

Secondary

Percentage of Participants With Medically Attended AEs (MAAEs)

MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.

Time frame: From first vaccination (Day 1) up to 6 months post second vaccination (Day 270)

Population: Safety Set included all enrolled participants who received at least 1 dose of TDV.

Arm	Measure	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Medically Attended AEs (MAAEs)	50.5 percentage of participants

Secondary

Percentage of Participants With Serious Adverse Events (SAEs)

A SAE was defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.

Time frame: From first vaccination (Day 1) up to end of study (Approximately 3 years)

Population: Safety Set included all enrolled participants who received at least 1 dose of TDV.

Arm	Measure	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Serious Adverse Events (SAEs)	5.5 percentage of participants

Secondary

Percentage of Participants With Virologically Confirmed Dengue

Participants with febrile illness defined as fever ≥38°C on any 2 of 3 consecutive days were evaluated for dengue. Virologically confirmed dengue was defined as febrile illness with a positive serotype-specific RT-PCR (i.e. positive dengue detection RT-PCR).

Time frame: From first vaccination (Day 1) up to 6 months post second vaccination (Day 270)

Population: Safety Set included all enrolled participants who received at least 1 dose of TDV.

Arm	Measure	Value (NUMBER)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Percentage of Participants With Virologically Confirmed Dengue	6.0 percentage of participants

Secondary

Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country

The phenotype characterization of cellular immune response by country was assessed by ICS by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses \>500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per country (Panama and Philippines) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).

Time frame: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3

Population: ICS Subset 'by country based on T-cells' included participants from PPS who have IFN-γ ELISPOT responses \>500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.

Arm	Measure	Group	Value (MEDIAN)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.007000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.005670 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.002270 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.001915 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.000200 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.005531 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.002890 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.004470 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.002690 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000530 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.006400 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.000661 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.001810 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.000900 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.001440 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.010000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.000500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.001620 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.002490 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.002396 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.003580 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.002456 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.001240 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.005710 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.001590 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.000620 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.021500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.005000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.000985 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.001005 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.000012 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000702 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.001555 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.008590 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000895 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.003892 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.000656 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.000413 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.004500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.000025 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000261 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000631 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000982 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.001005 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.001485 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.003935 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.002005 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.001452 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.002448 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.002700 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.003832 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.006500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.001415 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.002695 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000100 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.002880 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.000456 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.000477 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000545 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.001695 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.001053 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.000645 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.002758 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.001065 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.003100 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.001170 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000004 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000035 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.000793 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000758 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.001486 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000070 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.001835 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.002825 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.001820 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.001265 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.004000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.002110 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.006810 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.005450 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.003720 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.002710 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.002890 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.004222 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.001700 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.003350 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.000850 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.000498 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.010000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.005670 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.003491 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.003270 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000679 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000515 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.001290 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.002120 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.001120 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.004140 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.004530 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.026000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.009230 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.003495 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.002598 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.001135 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.002045 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.001800 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.000702 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.008335 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.003275 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.001520 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.000365 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.000205 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.007000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.001500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.015000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.005090 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.001540 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.002393 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.001386 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.000740 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.000430 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.005400 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000660 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.001955 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.000002 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.005500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.004303 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.002138 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.000538 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.001599 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.000965 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.000766 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.003735 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.004910 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.000788 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.005000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.025500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.075000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.002406 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000503 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.001335 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.001095 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.000050 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.001055 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000380 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.003865 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000020 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.000050 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.000085 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.003500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.047000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.002624 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000760 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.002884 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000080 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000540 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.001050 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.001650 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.001330 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.000300 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.000584 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.010590 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.008500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.015000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.002010 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.047980 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.020970 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.001825 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.012063 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.004000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.001000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.018930 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.001680 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.011465 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.007000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.001000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.003760 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.00000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000860 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.001970 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.114125 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.002050 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.004335 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.002995 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.002000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.008500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.005735 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.001170 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.004390 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.074245 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.002180 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.001065 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.008865 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.065510 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.004090 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.094740 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.092920 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.018200 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.011000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.018000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.004155 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.006000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.129260 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.033420 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.019265 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.022820 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.001655 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.005000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.003560 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.001370 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.005000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.003500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.005000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.024675 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.004000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.005500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.013000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.001000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.010000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.004600 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.003364 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.013000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.021000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.010000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.007670 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.002920 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.001590 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.002230 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.006040 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.001650 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000985 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.016000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.005000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.002595 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.077000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.022915 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.004000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.004620 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.003210 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.009000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.001735 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.073630 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.014500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.093000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.002000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.021000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.001048 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.045815 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.001669 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.002000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.016169 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.009090 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.021940 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.037000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.001540 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.010000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.010000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.00000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.142870 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.001000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.00000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.000935 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.014000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.067000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.005610 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.022820 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.125320 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.172000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.009520 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.004000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.005470 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.005570 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.000795 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.001175 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.002250 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000837 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.000465 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.014000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.005580 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000895 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.010500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.008860 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.010000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.001030 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.001875 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.000812 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.002000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.001490 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.014000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.015970 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.009770 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.002390 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.001210 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.008000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000030 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.001620 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.003555 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.002380 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.001155 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.053520 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.021000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.061520 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.153500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.096615 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.005500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.006850 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.001175 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.003750 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.001295 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.039000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.018425 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.002000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.003500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.006905 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.003000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.016500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.010000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.011000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.001100 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.005090 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.003620 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.010000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000844 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.020000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.004695 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.099370 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.056525 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.001350 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells

Secondary

Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3

The phenotype characterization of cellular immune response was assessed by intracellular cytokine staining (ICS) by the frequency of total cluster of differentiation 4 (CD4)+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses \>500 SFC/million cells and availability of sufficient cells. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) cytokines for each peptide pool. Data is reported based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).

Time frame: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3

Population: ICS Subset 'by T-cells' included participants from PPS who have IFN-γ ELISPOT responses \>500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.

Arm	Measure	Group	Value (MEDIAN)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.001630 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.010000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.002110 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.010000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.009500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.005000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.003825 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.008340 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.003980 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.003350 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.001998 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.003410 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.001275 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.002908 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000105 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.002100 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.003720 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.001050 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.001085 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.002050 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.001100 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.000856 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.000850 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.001585 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000615 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.003545 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.002110 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.000587 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.005380 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.000860 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.003500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.007160 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.002500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.042500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.002810 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.002920 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.003350 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000727 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.001045 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.001500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.002070 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.000498 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.000990 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.001608 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000871 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.000080 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.000810 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.009000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.000750 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.002835 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000420 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.000210 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.001050 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.000150 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.002890 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.000910 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.009500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.029500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.006150 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.002450 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.002925 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000696 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.002520 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.002510 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.005110 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.002840 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000060 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000122 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000160 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.000090 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.001670 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.002310 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.001100 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.000048 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.001210 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.000180 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.000334 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.004010 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.008260 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.005000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.001350 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.015580 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.001210 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.001610 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.018180 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.140000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.140790 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.007490 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.061520 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.063490 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.001700 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.012000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.008000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.005565 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.004020 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.005155 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.106350 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.076145 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.001820 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.022310 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.021455 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.001500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.012000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.008500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.001320 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.010000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.007850 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000960 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.007340 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.116110 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.096230 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.004080 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.038000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.018850 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.004000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.012000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.012000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.004630 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.004430 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.004620 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.089000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.067000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.003060 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.015360 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.013000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.015000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.014000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.001360 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.001600 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.022915 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.022135 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.000434 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.003075 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.003400 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.005210 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.007000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.001925 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.001535 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.001015 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.014120 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.013923 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000100 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.003625 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.002915 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000100 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.003625 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.002915 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.001295 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000950 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.000856 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.006290 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.007770 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.002340 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.002380 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.003000 percentage of T cells

Secondary

Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity

The phenotype characterization of cellular immune response by dengue Baseline seropositivity status was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses \>500 SFC/million cells and availability of sufficient cells. Seropositive was defined as a reciprocal neutralizing titer (MNT50) \>=10 for one or more dengue serotypes. Seronegative was defined as titer value of \<10 for all 4 serotypes. The peptide pools included NS1, NS3 and NS5 for DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per Baseline seropositivity status (Seropositive and Seronegative) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).

Time frame: 1 month post first vaccination (Day 30); pre-second vaccination (Day 90); 1 and 6 months post second vaccination (Days 120 and 270); Years 1, 2, and 3

Population: ICS Subset 'by Baseline seropositivity status based on T-cells' included participants from PPS who have IFN-γ ELISPOT responses \>500 SFC/million PBMCs and availability of sufficient cells. Number analyzed=participants with data available for analysis for specific category.

Arm	Measure	Group	Value (MEDIAN)
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.013000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.001058 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.009000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.001500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.002612 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.002150 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.005720 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.004740 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.000631 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.006710 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.011000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.003480 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.003720 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000842 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.002705 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.000190 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.023000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.000975 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.003744 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.002960 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000645 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.000850 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.028000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.002885 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.002915 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.000070 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.003220 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000544 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.000702 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000070 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.004735 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000530 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.057000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.003100 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000745 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.005140 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.001540 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.001520 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.003110 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.001235 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.002710 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.000280 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.000621 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.000020 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.001583 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.003592 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.000523 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.009500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.001490 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000686 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.001090 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.005380 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.000180 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.007000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.001245 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.010000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.008000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.044000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.001500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.008790 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.002630 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.003410 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000320 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.003980 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000880 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.002890 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.000010 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.001110 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.001740 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.019000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.001650 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.001430 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.001470 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.000330 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.011000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.003620 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000760 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.003230 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.002795 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.001190 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000613 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000515 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.002470 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.001500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.001500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.001510 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000860 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.001200 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.002190 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.001590 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.007655 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.034000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.010000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.001325 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.020000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000920 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.000170 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.006000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.000522 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.001420 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.004000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.000746 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.003070 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.000017 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000490 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.001810 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.002885 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.000578 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.000410 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.001050 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000588 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.001880 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.002055 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.003785 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.005000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.005255 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.002510 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.002275 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000557 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000380 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.006500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.001390 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.001230 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.010405 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.000150 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.005531 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000760 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.003300 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.016000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.001460 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.002270 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.001220 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.002070 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.000835 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.000450 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.004000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.001570 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.001934 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.011430 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.003000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.000065 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.006490 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.002490 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.000190 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.000010 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.000900 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.006000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.002000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.018000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.000864 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.002170 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.010000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.004355 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.001000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.002170 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.002720 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.001650 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.006000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.001050 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000500 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.000190 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.004985 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.000803 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.000798 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000120 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.005735 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000778 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.002170 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.021000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.018000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.001540 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.018190 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.108250 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.150000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.007750 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.065380 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.053520 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.002000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.005000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.018000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.015000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000013 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.004660 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.003260 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000785 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000383 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.002893 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.103350 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.081000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.002390 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.039000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.026425 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.002000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.008405 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.005450 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.001400 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.010000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.012000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.001540 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.007155 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.144565 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.102525 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.004280 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.046825 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.034610 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.001500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.004500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.018000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.016500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.008760 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.003960 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.003430 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.099000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.070000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.003060 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.022120 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.015270 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.003000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.026000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.015000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.000170 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.002460 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.033910 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.036130 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.003000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.003000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.001000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.006000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.007000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.002100 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.001700 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.001720 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.012470 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.007735 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.002707 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.002955 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000040 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000500 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.004000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.003000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.025000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.015650 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000670 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.004920 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.004580 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.008310 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.004000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000060 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.001420 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 mL: Panama: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 30	0.003610 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 270	0.055015 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 270	0.069910 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 270	0.008115 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 3	0.004220 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 3	0.007770 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 270	0.004575 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 30	0.002000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 270	0.002605 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 270	0.000411 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 30	0.101275 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 120	0.008000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 120	0.009000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 120	0.006000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 3	0.000090 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 120	0.003000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 120	0.002000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 30	0.051500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 3	0.002320 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 120	0.016280 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 120	0.024000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 30	0.007370 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 3	0.001070 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 120	0.004080 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 30	0.009560 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 120	0.078900 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 120	0.093000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 120	0.007850 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 120	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 3	0.001270 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 120	0.006000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 120	0.010000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 3	0.001830 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 3	0.008000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 120	0.001320 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 90	0.009500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 2	0.007800 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 90	0.018000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 30	0.117545 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 2	0.012220 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 90	0.001000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000500 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 90	0.015420 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 90	0.017000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 90	0.001535 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 30	0.168175 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Day 90	0.069105 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Day 90	0.107000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 30	0.015540 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 2	0.003380 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Day 90	0.006540 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 30	0.017000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 2	0.001140 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 3	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Year 1	0.003150 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Day 90	0.004563 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Year 1	0.003800 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Year 1	0.001300 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Day 90	0.005880 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Day 30	0.001695 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS5-2, Year 1	0.010120 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS3-2, Year 1	0.013000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS5-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 90	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Year 1	0.004420 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 1	0.001200 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 1	0.002000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Day 30	0.001330 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Year 1	0.007000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 1	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS5-2, Day 270	0.006000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 270	0.004000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS3-2, Day 30	0.006000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS3-2, Year 2	0.000042 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS3-2, Day 270	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Day 30	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS5-2, Year 2	0.001340 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa-, DENV-2, NS1-2, Day 270	0.001000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS5-2, Day 270	0.008945 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa+, DENV-2, NS1-2, Day 30	0.000245 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS3-2, Day 270	0.007160 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2-TNFa-, DENV-2, NS1-2, Day 270	0.003350 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2-TNFa+, DENV-2, NS1-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg+IL2+TNFa-, DENV-2, NS3-2, Year 2	0.000000 percentage of T cells
TDV 0.5 ml: Philippines: CD8+ T Cells	Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity	IFNg-IL2+TNFa+, DENV-2, NS5-2, Day 270	0.000000 percentage of T cells

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026

Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination

Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually Up to 3 Years

Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3 by Dengue Baseline Seropositivity Status

Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First, Pre- Second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 by Country

Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3

Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants >10 Years of Age

Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination

Percentage of Participants Experiencing Unsolicited Adverse Events (AE)

Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, Pre-second Vaccination, and 1, 6 Months Post Second Vaccination and Then Annually up to 3 Years

Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, Pre Second Vaccination, 1, 6 Months Post Second Vaccination and Annually up to 3 Years

Percentage of Participants With Cellular Immune Responses to TDV:1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3, by Dengue Baseline Seropositivity Status

Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 1 and 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3 Assessed by Country

Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination, Pre-second Vaccination, 6 Months Post Second Vaccination, and Annually at Years 1, 2, and 3

Percentage of Participants With Cellular Immune Response to TDV in Participants >10 Years of Age

Percentage of Participants With Medically Attended AEs (MAAEs)

Percentage of Participants With Serious Adverse Events (SAEs)

Percentage of Participants With Virologically Confirmed Dengue

Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Peptides,1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Country

Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Peptides at 1Month Post First Vaccination,Pre-second Vaccination;1,6Months Post Second Vaccination, Annually at Years1,2,3

Phenotype Characterization of Cellular Immune Response by Percentage of Total T Cells DENV-2 NS Peptides at 1Month Post First Vaccination,Pre Second Vaccination;1,6Months Post Second Vaccination,Annually at Years1,2,3 by Dengue Baseline Seropositivity